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In South Africa (SA), nearly one person in every hundred develops 
active tuberculosis (TB) each year (834 cases per 100 000 people). 
Nearly two-thirds (61%) of all notified TB cases are HIV-infected, 
and an estimated 96 000 persons die from TB each year, 75% of 
whom are HIV co-infected.[1] Treatment for drug-susceptible 
tuberculosis (DS-TB) is provided at primary healthcare clinics 
(PHCs) using a standard regimen that requires daily medication 
for 6 - 8 months.
Despite the large number of patients treated in SA, there are few 
descriptions in the published literature of drug-susceptible patient 
characteristics, mode of diagnosis or treatment outcomes in routine 
public sector treatment programmes. What is evident from the 
published literature is that, even with clear national guidelines in 
place,[2,3] practices and outcomes vary across the country. Differences 
in rates of treatment success are substantial, ranging from nearly 83% 
(Western Cape) to less than 58% (Limpopo) at the provincial level, 
and from 90% (uThungulu, KwaZulu-Natal) to just 47% (Vhembe, 
Limpopo) at the district level.[4] Methods for diagnosis vary, with 
nationally reported data suggesting that 40% of pulmonary TB 
cases are clinically diagnosed,[1] although much higher rates may be 
observed among HIV-positive patients.[5] Directly observed therapy 
(DOT) coverage rates and type of supervisor may also vary between 
facilities and by treatment phase. Data from Gauteng, KwaZulu-Natal 
and Mpumalanga provinces in 2009 indicated that while nearly all 
patients (97%) received DOT support through the intensive phase of 
treatment, only 60% of patients received DOT support throughout 
the full treatment course.[6]
Objective
To contribute to the evidence base on public sector TB treatment 
service delivery, we constructed a retrospective cohort of adult 
TB patients treated at three public sector clinics in the city of 
Johannesburg. Using medical record data, we report patient 
characteristics, HIV status and TB history, diagnosis and laboratory 
information, treatment characteristics, DOT supervision and 
treatment outcomes for this cohort.
Methods
Study sites
The study was conducted at three PHCs in Region A of the 
Johannesburg Metropolitan Municipality (JHB) in Gauteng, SA. We 
selected a convenience sample of clinics with specific characteristics. 
Characteristics considered in the selection of study clinics included 
the volume of TB patients initiating TB treatment per month, the 
catchment population represented by the clinics and their location 
within the JHB region. At the time of the study, clinic 1 PHC, 
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located in Ivory Park township, collected sputum samples from an 
average of 55 persons per month, with 6 patients per month testing 
acid-fast bacillus (AFB) smear microscopy-positive (District Health 
Information Software (DHIS), South Africa – unpublished data, 
2011 - 2012). Clinic 2 PHC, located in Ebony Park township, tested 
a monthly average of 61 persons for TB, of whom 5 per month were 
smear microscopy-positive (DHIS – unpublished data, 2011 - 2012). 
Clinic 3 PHC, located in Diepsloot, a large informal settlement, tested 
an average of 82 persons per month for TB, of whom an average of 
8 per month tested smear microscopy-positive (DHIS – unpublished 
data, 2011 - 2012). All three clinics followed national guidelines for 
drug-sensitive TB treatment in adults and adolescents in place at 
the time.[2] Standards of care under these guidelines are detailed in 
Table 1.
Study population and data
In May 2013, a retrospective cohort was created from a census of 
adult (≥18 years of age) TB patients registered in clinic case registers 
Table 1. SA national guidelines for diagnosing and treating drug-sensitive TB during the study period (2011 - 2012)
Diagnosis Diagnosis by AFB sputum smear microscopy. Two specimens sent to the National Health Laboratory 
Service (NHLS) laboratory associated with the clinic. Follow-up testing could be requested for patients 
who were AFB– but still TB symptomatic, including chest X-ray at nearby hospitals, or liquid culture 
and/or line probe assay at the provincial NHLS laboratory. Suspects with a history of prior TB treatment 
provided a third sputum sample for culture and DST. (Note: In 2011 SA began implementing a switch 
from AFB smear microscopy to GeneXpert MTB/RIF (Cepheid, USA) for the initial diagnosis of 
pulmonary TB, but the study period predated this roll-out.) 
Registration and treatment initiation At the time of diagnosis, patients are either initiated on treatment and registered at the diagnosing facility, or 
initiated on treatment and immediately referred for registration and continuation of treatment at the most 
appropriate PHC based on the patient’s home or work address. Those who are referred from TB hospitals to 
PHCs are provided with TB medication for 7 days and, if possible, are delivered to the clinic, collected by the 
clinic, or accompanied by a treatment supervisor or social worker. Where this is not possible, the hospital is 
expected to follow up directly with clinics to confirm whether the patient arrived. Patients are considered to 
have ‘transferred in’ if they were registered for TB treatment by another facility.
Treatment regimen Standard 6-month chemotherapy regimen (regimen 1) of rifampicin (R), isoniazid (H), pyrazinamide (Z) and 
ethambutol (E), which is administered daily as a fixed-dose combination tablet (RHZE 150, 75, 400, 275 mg) 
during an initial 2-month intensive phase, followed by a 4-month continuation phase of daily R and H (fixed-
dose tablet containing RH 150, 75 mg or 300, 150 mg, depending on weight).[2] Guidelines recommended 
pyridoxine treatment for selected TB clients (i.e. if pregnant, diabetic, epileptic or abusing alcohol).[2]
Treatment monitoring Collection of a sputum specimen for smear microscopy at 2 months and 6 months. Patients with 
extrapulmonary TB or with a clinical diagnosis are assessed through clinical monitoring.
Treatment extensions The intensive phase could be extended to 3 months in the absence of smear conversion, defined as 
remaining AFB+ after 2 months of treatment. The continuation phase could be extended to 7 months in 
the event of severe or complicated disease such as miliary TB, meningitis, pericarditis, peritonitis, spinal 
or intestinal TB, or bilateral and extensive plural effusions. If a treatment interruption occurred lasting <2 
months, treatment could also be extended by the number of days that the patient did not take treatment.
Resistance DST is performed for retreatment cases prior to starting treatment, for individuals who fail to smear-convert 
at the end of the intensive phase of treatment and for treatment failures. (Note: As of 2013, there was 
national coverage of GeneXpert MTB/RIF and therefore universal testing for rifampicin resistance.[3])
Treatment outcomes Patients considered cured were smear- or culture-positive at treatment initiation and smear- or culture-
negative in the final month of treatment and on at least one occasion in the previous 30 days. Treatment 
completion refers to patients who completed treatment but did not meet the criteria to be classified as 
cured or as a treatment failure. Treatment failure refers to patients who were smear- or culture-positive at 
treatment initiation and remained smear- or culture-positive in the continuation phase, or who became 
smear- or culture-positive any time after treatment initiation, or whose DSTs indicated the presence of 
rifampicin resistance. Those who missed >2 consecutive months of treatment were considered to be lost 
to follow-up, while those who died included deaths from any reason during the course of treatment. 
Individuals who moved to another facility were recorded as transferred out; if the treatment outcome was 
unknown, the patient was assigned a missing outcome.
Co-infection with HIV Patients co-infected with HIV were eligible for initiation on ART with a CD4 count below 350 cells/µL or 
if there was evidence of MDR-TB or extensively drug-resistant TB, irrespective of CD4 count. Those who 
developed TB while on ART remained on ART throughout TB treatment. If eligible to begin ART, those 
who presented with TB before initiating ART were initiated on ART as soon as TB therapy was tolerated 
(typically within 2 - 4 weeks of initiating TB therapy, up to a maximum of 8 weeks). The standard first-
line ART regimen consisted of tenofovir, lamivudine or emtricitabine, and efavirenz (which is generally 
preferred over nevirapine in TB patients). Co-trimoxazole preventive therapy was recommended and 
ideally initiated before starting ART.
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at the three sites between 1 April 2011 and 31 March 2012. Patients 
with missing outcomes were included in a descriptive analysis of the 
cohort but excluded from the final outcome analysis.
Data were extracted from National TB Programme (NTP) clinic 
cards and TB case registers routinely maintained at each study site. 
The data collected included age, sex, weight, treatment clinic, diag-
nosis method and date, registration and treatment start dates, trans-
fer in, treatment history, type of TB, treatment regimens, laboratory 
results and dates, drug susceptibility testing (DST) results, type of 
treatment supervisor during both the intensive and continuation 
phases of treatment, HIV and antiretroviral therapy (ART) status 
at TB treatment initiation, CD4 count, and treatment outcomes and 
dates. The treatment supervisor was classified as formal supervision 
(including facility based, community caregiver or employer) and 
family- or self-administered treatment. Longitudinal information 
concerning HIV treatment, including ART regimens and laboratory 
results, was not available in the TB cards.
We attempted to locate missing data by checking TB case registers, 
referral slips and laboratory reports left in TB clinic cards. Individuals 
with blank DST results were assumed to have DS-TB; those with 
evidence of resistance were included in the baseline analysis of 
the cohort but later excluded from the final outcome assessment. 
Individuals who were registered for TB treatment on more than one 
occasion during the study period could be identified, as their TB 
cards were stapled together.
Smear microscopy status at treatment initiation could be 
determined only for pulmonary TB cases with: (i) a bacteriological 
diagnosis; or (ii) a clinical diagnosis if smear or culture results were 
also available. Scanty smears were categorised as smear-positive 
according to the SA NTP guidelines of 2009,[2] and smear conversion 
(i.e. conversion from smear-positive at treatment initiation to smear-
negative) was estimated using laboratory results from the end of 
the intensive phase of treatment. Since the TB clinic cards did not 
distinguish between when sputum samples were collected and results 
obtained, it was not possible to discern whether patients with missing 
smear results had sputum samples collected.
Outcomes and statistical analysis
Treatment outcomes were defined according to the 2009 SA NTP 
guidelines (cured, treatment completed, treatment failed, died, lost 
to follow-up or transferred out), which were in use during the study 
period and recorded in the patient records (Table 1).[2]
We first summarised baseline demographic and clinical charac-
teristics, mode of diagnosis, method of supervision, smear and culture 
conversion and treatment outcomes as proportions or medians 
with interquartile ranges (IQRs). We then investigated associations 
between baseline demographic and clinical characteristics and 
treatment outcomes. We modelled the risk of treatment success (a 
composite outcome of cured and completed treatment) and poor 
treatment outcome (a composite of died and failed) using modified 
Poisson regression with a robust error variance.
To obtain adjusted relative risk (RR) estimates, a priori 
confoun ders were identified and included in models for treatment 
success (adjusted for age, sex, treatment history and treatment 
super visor) and poor treatment outcome (adjusted for age, sex 
and HIV status).
Ethical considerations
Approval for analysis was granted by the Human Research Ethics 
Committee (Medical) of the University of the Witwatersrand 
(clearance certificate number M130119) and the City of Johannesburg 
Health Department.
Results
Baseline characteristics
During the study period, 618 cases registered for TB treatment 
across the three facilities (Fig. 1). Seventy-four were not eligible 
for the study (63 minors, 11 missing files), leaving 544 patients 
included in the analysis of baseline characteristics. Fifty-six percent 
of patients were male (306/544) and the median age was 35 years 
(IQR 29 - 41). Most (86%) were new TB cases and most (81%) had 
pulmonary TB. Seventy-one percent of cases were HIV co-infected 
(Table 2).
Among the pulmonary TB cases assessed for smear microscopy 
status (n=408), 58% were smear-positive at treatment initiation (61% 
among new cases and 44% among retreatment cases), and 16% were 
Registered for TB treatment
N=618
<18 years of age
n=63
File not found
n=11
Eligible for study
n=544
Outcome missing
n=1
Transfer out
n=48
(outcome not available)
Included in outcome analysis
n=495 cases
(from 490 unique patients)*
Cured
n=222
Treatment completed
n=172
Lost to follow-up
n=55
Died
n=40
Treatment failure
n=6
Fig. 1. Study enrolment and patient outcomes. (*Some patients were 
registered as two separate cases during the study period, once as a new case 
and once as a retreatment case.)
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smear-negative; the remainder (26%) did not indicate whether smear 
specimens were collected or tested.
Diagnosis and treatment initiation
Smear microscopy was the most common method of diagnosis 
(45%), followed by X-rays (30%), culture (5%), GeneXpert MTB/
RIF (4%), aspiration/biopsy (3%), cerebrospinal fluid (2%) and 
ultrasound (<1%). Among HIV-positive cases, 34% of patients 
(130/388) were diagnosed with TB clinically. Some individuals with 
an unknown method of diagnosis (12%) may have been diagnosed 
based on clinical symptoms alone, though it is unclear how many 
patients fell into this category, as symptom-based diagnoses were not 
recorded as such in the TB clinic cards.
Relatively few patients in the cohort initiated treatment at a study 
clinic. Nearly one-fifth (101/544, 19%) transferred in, primarily from 
within Gauteng (75/101, 75%), followed by Limpopo (11/101, 11%). 
Among those with no record of transferring in, over two-thirds of 
patients (308/443, 70%) initiated treatment prior to registering at a 
study clinic, suggesting that these individuals were first diagnosed at a 
non-study site, given a 1-week ‘starter’ supply of treatment medication, 
and referred for registration and continuation of treatment at a study 
site. Among these 308 individuals, the median time from treatment 
initiation to registration at a study clinic was 11 days (IQR 6 - 21).
Guideline compliance
When compliance with treatment guidelines was assessed, we found 
96% of retreatment cases (72/75) had a record of receiving streptomycin 
injections during the intensive phase, as per guidelines in place at the 
time of treatment.[2] Nearly two-thirds (63%, 341/544) of patients 
had a record of pyridoxine treatment and ART was recorded for 40% 
(156/388) of HIV-infected patients. For patients with HIV infection, 
guidelines also indicated concomitant co-trimoxazole prophylaxis, 
however this was only reported for a quarter (28%, 153/388) of eligible 
patients. Other non-regimen drugs prescribed included vitamin B 
complex (63%, 343/544), vitamin C (26%, 143/544), ofloxacin (<1%, 
2/544) and dapsone (<1%, 2/544). Both of the patients prescribed 
ofloxacin had DST results available, with one indicating multidrug-
resistant (MDR) TB and the other indicating resistance to rifampicin. 
The quality of record-keeping for medications prescribed varied 
substantially by clinic, with clinics  1 and 3 recording other non-
regimen drugs (e.g. vitamins) for 98% (125/127) and 88% (219/250) of 
patients, respectively, compared with just 2% (4/167) at clinic 2.
Supervision
Supervision type was reported for 81% of patients (441/544). Among 
those whose supervision type was reported, family or self-supervision 
Table 2. Baseline characteristics of the total cohort (N=544)
Characteristics
Sex female, n (%) 238 (43.8)
Age (yr), median (IQR) 35 (29 - 41)
Weight (kg)
Median (IQR) 54.4 (48.9 - 62.0)
Missing, n (%) 35 (6.4)
Patient category, n (%)
New patient 469 (86.2)
Retreatment 75 (13.8)
Classification of disease, n (%)*
Pulmonary TB 443 (81.4)
Extrapulmonary TB 100 (18.4)
Missing 1 (0.2)
Smear status, n (%)†
Smear-positive 237 (58.1)
Smear-negative 65 (15.9)
Missing 106 (26.0)
Culture status, n (%)†
Positive 16 (3.9)
Negative 1 (0.2)
Missing 391 (95.8)
HIV status
Positive 388 (71.3)
Negative 101 (18.6)
Missing 55 (10.1)
CD4 count (cells/µL)‡
Median (IQR) 110.5 (51.0 - 236.0)
Missing, n (%) 70 (18.0)
ART, n (%)‡
On ART 156 (40.2)
Not on ART 122 (31.4)
Missing 110 (28.4)
Method of diagnosis, n (%)
Smear microscopy 244 (44.9)
X-rays 161 (29.6)
Culture 29 (5.3)
GeneXpert MTB/RIF 22 (4.0)
Aspiration/biopsy 15 (2.8)
Cerebrospinal fluid 9 (1.7)
Ultrasound 1 (0.2)
Missing 63 (11.6)
Treatment supervisor (intensive phase), n (%)
Family- or self-administered 278 (51.1)
 Formal supervision (clinic, community or 
employer)
163 (30.0)
Supervisor unknown 103 (18.9)
Continued ...
Table 2. (continued) Baseline characteristics of the total cohort 
(N=544)
Characteristics
Treatment supervisor (continuation phase), n (%)
Family- or self-administered 245 (47.9)
 Formal supervision (clinic, community or 
employer)
82 (16.0)
Supervisor unknown§ 185 (36.1)
*Individuals with both pulmonary TB and extrapulmonary TB (n=8) classified here as 
pulmonary TB.
†Excludes individuals with extrapulmonary TB (n=100/544) and those with a clinical diagnosis 
and no bacteriological tests (n=36/544), as they are assessed through clinical monitoring.
‡Among HIV-positive patients only.
§Excludes individuals who died, failed treatment, were lost to follow-up or transferred out 
before the continuation phase of treatment (n=32/544).
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was most common (intensive phase 63% of 441, continuation phase 
75% of 327), but there was a large range of family- or self-supervision 
rates across clinics (intensive phase: 75% for clinic 1, 87% for clinic 2, 
43% for clinic 3; continuation phase: 96% for clinic 1, 97% for clinic 2, 
53% for clinic 3). Among retreatment cases, 9% (7/75) were reported 
as self-supervised and 24% (18/75) had no treatment supervisor 
listed during the intensive phase, although all had documentation 
of receiving anti-TB injections from the clinic; all retreatment cases 
were therefore assumed to be on facility-based supervision during 
the intensive phase. Supervision type was missing for 19% (103/544) 
of cases in the intensive phase and in 36% (185/512) of cases that 
reached the continuation phase of treatment.
Treatment outcomes
Because outcomes were not available for 49 patients (9%), of whom 
48 transferred out prior to reaching an outcome and 1 was missing 
an outcome, 495 patients were included in the final outcome analysis. 
Just over half (52%, 124/237) of smear-positive cases achieved smear 
conversion at the end of the intensive phase of treatment, while 9% 
(22/237) did not smear-convert and the remaining 38% (91/237) were 
missing the laboratory results needed to assess smear conversion. Nearly 
half of all cases (45%) were cured and another 35% completed treatment, 
leading to an overall treatment success rate of 80%. Eleven percent were 
lost to follow-up, 1% failed treatment, and 8% died (Table 3). The 
rate of treatment success was 80% among HIV co-infected patients, 
Table 3. Treatment outcomes according to patient characteristics, among individuals with outcomes available (N=495)
Characteristics
Treatment 
success,* 
n (%)
Cured, 
n (%)
Treatment 
completed, 
n (%)
Lost to 
follow-up, 
n (%)
Treatment 
failure, 
n (%) Died, n (%) Total, n
Total 394 (79.6) 222 (44.8) 172 (34.7) 55 (11.1) 6 (1.2) 40 (8.1) 495
Sex
Male 222 (78.2) 126 (44.4) 96 (33.8) 35 (12.3) 3 (1.1) 24 (8.5) 284
Female 172 (81.5) 96 (45.5) 76 (36.0) 20 (9.5) 3 (1.4) 16 (7.6) 211
Age (yr)
18 - 30 122 (81.9) 69 (46.3) 53 (35.6) 20 (13.4) 2 (1.3) 5 (3.4) 149
≥31 - 45 206 (80.2) 111 (43.2) 95 (37.0) 26 (10.1) 1 (0.4) 24 (9.3) 257
>45 66 (74.2) 42 (47.2) 24 (27.0) 9 (10.1) 3 (3.4) 11 (12.4) 89
HIV status
Negative 78 (83.0) 51 (54.3) 27 (28.7) 10 (10.6) 3 (3.2) 3 (3.2) 94
Positive, on ART 110 (80.3) 50 (36.5) 60 (43.8) 13 (9.5) 0 (0) 14 (10.2) 137
Positive, not on ART 93 (80.2) 49 (42.2) 44 (37.9) 12 (10.3) 0 (0) 11 (9.5) 116
Positive, ART unknown 81 (80.2) 49 (48.5) 32 (31.7) 9 (8.9) 2 (2.0) 9 (8.9) 101
Unknown HIV status 32 (68.1) 23 (48.9) 9 (19.2) 11 (23.4) 1 (2.1) 3 (6.4) 47
TB treatment history
New TB case 339 (78.7) 195 (45.2) 144 (33.4) 51 (11.8) 6 (1.4) 35 (8.1) 431
Retreatment case 55 (85.9) 27 (42.2) 28 (43.8) 4 (6.3) 0 (0) 5 (7.8) 64
Supervision type (intensive phase)
Supervised (formal) 116 (82.3) 64 (45.4) 52 (36.9) 15 (10.6) 1 (0.7) 9 (6.4) 141
Family- or self-administered 200 (78.4) 108 (42.4) 92 (36.1) 30 (11.8) 4 (1.6) 21 (8.2) 255
Unknown 78 (78.8) 50 (50.5) 28 (28.3) 10 (10.1) 1 (1.0) 10 (10.1) 99
Supervision type (continuation phase)†
Supervised (formal) 65 (84.4) 38 (49.4) 27 (35.1) 7 (9.1) 1 (1.3) 4 (5.2) 77
Family- or self-administered 211 (90.6) 115 (49.4) 96 (41.2) 11 (4.7) 3 (1.3) 8 (3.4) 233
Unknown 118 (70.7) 69 (41.3) 49 (29.3) 31 (18.6) 2 (1.2) 16 (9.6) 167
Clinic
Clinic 1 97 (78.9) 73 (59.3) 24 (19.5) 13 (10.6) 3 (2.4) 10 (8.1) 123
Clinic 2 126 (79.2) 65 (40.9) 61 (38.4) 19 (11.9) 1 (0.6) 13 (8.2) 159
Clinic 3 171 (80.3) 84 (39.4) 87 (40.8) 23 (10.8) 2 (0.9) 17 (8.0) 213
Smear status at treatment initiation‡
Smear-positive 166 (76.1) 156 (71.6) 10 (4.6) 31 (14.2) 5 (2.3) 16 (7.3) 218
Smear-negative 44 (77.2) 19 (33.3) 25 (43.9) 8 (14.0) 0 (0) 5 (8.8) 57
Unknown 84 (86.6) 43 (44.3) 41 (42.3) 6 (6.2) 1 (1.0) 6 (6.2) 97
*‘Cured’ + ‘treatment completed’.
†Excludes individuals who died, failed treatment or were lost to follow-up before the continuation phase of treatment (18/495).
‡Excludes individuals with extrapulmonary TB (91/495) or those with a clinical diagnosis and no bacteriological tests (32/495) as they are assessed through clinical monitoring.
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79% among new and relapse cases, and 83% among retreatment cases 
(excluding relapse). The cure rate was 71% (140/196) among new 
smear-positive cases and 73% (16/22) among retreatment smear-
positive cases. Among patients who died, the median time to death was 
78.5 days (IQR 55.0 - 124.5) from treatment initiation.
Comparing available laboratory results with outcomes recorded in 
patient records revealed that more than two-thirds (151/222, 68%) 
of patients who were classified as cured were missing the laboratory 
tests needed to independently verify this outcome classification. 
For example, among the 219 cured pulmonary TB cases, one-fifth 
(45/219, 21%) lacked evidence of a positive bacteriological test 
at treatment initiation. Among cured pulmonary TB cases with 
a positive bacteriological test at baseline (174/219), more than 
half (104/174, 60%) were missing evidence of being smear- or 
culture-negative in the final month of treatment and on at least one 
occasion in the previous 30 days. Among cured extrapulmonary 
TB cases (n=3), 2 patients had no laboratory results available to 
indicate cure. Of the 6 patients who were classified as having failed 
treatment, 4 were smear-positive at treatment initiation but lacked 
smear results from the continuation phase needed to confirm this 
outcome classification. Another 2 individuals appeared to have failed 
treatment but were classified as having completed treatment and died 
(i.e. treatment failure preceded date of death), respectively.
Adjusted models did not show any association between sex, HIV status, 
TB treatment history, or treatment supervisor and the risk of treatment 
success (Table 4). Older age (>45 years) was suggestive of an increase in 
the risk of poor treatment outcomes compared with younger age (18 - 
30  years) (adjusted RR 3.33, 95% confidence interval (CI) 1.33 - 8.32).
Resistance testing
The SA NTP guidelines[2] recommend DST for retreatment cases 
(n=75) prior to starting treatment, for individuals who fail to smear-
Table 4. Risk of treatment success (cured or treatment completed) and poor treatment outcome (died or failed), according to patient 
characteristic (N=495)
Characteristics and exposure category
Treatment success (n=394) Poor treatment outcome (n=46)
Crude RR
(95% CI) Adjusted RR (95% CI)
Crude RR
(95% CI) Adjusted RR (95% CI)
Age (yr)
18 - 30 Ref Ref Ref Ref
31 - 45 0.98 (0.89 - 1.08) 1.02 (0.81 - 1.30) 2.07 (0.92 - 4.67) 1.96 (0.83 -  .65)
>45 0.91 (0.78 - 1.05) 0.91 (0.67 - 1.23) 3.35 (1.40 - 7.98) 3.33 (1.33 - 8.32)
Sex
Male Ref Ref Ref Ref
Female 1.04 (0.95 - 1.14) 1.00 (0.82 - 1.24) 0.95 (0.54 - 1.66) 1.03 (0.57 - 1.89)
HIV status
Negative Ref Ref Ref Ref
Positive, on ART 0.97 (0.86 - 1.09) 0.97 (0.72 - 1.31) 1.51 (0.60 - 3.80) 1.53 (0.58 - 4.06)
Positive, not on ART 0.97 (0.85 - 1.10) 0.97 (0.72 - 1.32) 1.52 (0.58 - 3.96) 1.46 (0.54 - 3.99)
Positive, ART unknown 0.97 (0.85 - 1.10) 0.99 (0.72 - 1.36) 1.68 (0.65 - 4.38) 1.62 (0.59 - 4.43)
Unknown HIV status 0.82 (0.66 - 1.02) 0.86 (0.57 - 1.30) 1.33 (0.40 - 4.50) 1.28 (0.36 - 4.54)
TB treatment history
New patient Ref Ref Ref Not in model
Retreatment 1.09 (0.98 - 1.22) 1.11 (0.76 - 1.64) 0.82 (0.34 - 2.00) Not in model
Clinic
Clinic 1 Ref Not in model Ref Not in model
Clinic 2 1.00 (0.89 - 1.13) Not in model 0.83 (0.41 - 1.71) Not in model
Clinic 3 1.02 (0.91 - 1.14) Not in model 0.84 (0.43 - 1.65) Not in model
Treatment supervisor 
(intensive phase)
Supervised (formal) Ref Ref Ref Not in model
Family- or self-administered 0.95 (0.86 - 1.05) 0.90 (0.62 - 1.30) 1.38 (0.68 - 2.79) Not in model
Supervisor unknown 0.96 (0.84 - 1.09) 1.11 (0.76 - 1.63) 1.57 (0.69 - 3.55) Not in model
Treatment supervisor (continuation phase)*
Supervised (formal) Ref Ref Ref Not in model
Family- or self-administered 1.07 (0.97 - 1.19) 1.19 (0.82 - 1.72) 0.73 (0.26 - 2.03) Not in model
Supervisor unknown 0.84 (0.73 - 0.96) 0.83 (0.59 - 1.18) 1.66 (0.64 - 4.31) Not in model
*Excludes individuals who died, failed treatment or were lost to follow-up before the continuation phase of treatment (18/495).
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convert at the end of the intensive phase of treatment (n=22), and for 
treatment failures (n=6). Despite this, only 2% (2/97) of these patients 
had a record of DST being performed, including one with evidence of 
resistance to rifampicin and isoniazid (i.e. MDR-TB), and the other 
with evidence of resistance to rifampicin. An additional 4 patients 
had DST results but no clear indication for drug susceptibility testing; 
2 showed blank drug resistance results, 1 had MDR-TB and 1 was 
resistant to both ethambutol and streptomycin. All individuals with 
evidence of drug resistance transferred out and are therefore not 
included in our analysis of treatment outcomes. Of the 6 patients with 
DST results, only 1 had evidence of drug sensitivity recorded.
Discussion
In this retrospective analysis of drug-sensitive TB treatment in 
Johannesburg, the three study clinics achieved reasonable rates of 
treatment success, averaging 80%. When compared with nationally 
reported data, the study sites had higher rates of treatment success 
among previously treated cases (excluding relapse) (83% v. 69%) 
and similar rates of treatment success among new and relapse (79% 
v. 78%) and HIV-positive cases (80% v. 76%).[1] Smear-positive cure 
rates were substantially lower (72%) than the 85% target set in the 
2009 SA NTP guidelines,[2] and missing smear and culture results 
meant that the outcomes of more than two-thirds of patients reported 
as cured could not be independently verified.
We also note that only six patients had any record of DST 
taking place, despite 97 being eligible for DST. At best, this lack 
of documentation of laboratory results makes it difficult to assess 
adherence to guidelines; at worst, patients with a high potential for 
drug resistance are being missed, though it is unclear whether missing 
DST results necessarily implies testing was not done. An estimated 
1.8% of new TB cases and 6.7% of retreatment cases have MDR-TB,[1] 
suggesting that our cohort of 469 new cases and 75 retreatment cases 
may have had more than a dozen MDR-TB cases in need of second-
line treatment, considerably more than the one individual with 
MDR-TB identified in this cohort. Our study therefore offers further 
justification for universal testing for resistance to rifampicin with the 
national adoption of Xpert MTB/RIF (Cepheid, USA) in 2011 as the 
first-line diagnostic test for TB.
Although we found that three-quarters (409/544) of patients either 
transferred in or initiated treatment at a non-study site, we could not 
assess what fraction of patients may have failed to link to care after 
referral from other sites. Yet recent evidence from within SA suggests 
that referral outcomes may be unacceptably poor. Data from a district 
hospital in rural KwaZulu-Natal show that among HIV co-infected 
patients initiating TB treatment, 8% of those down-referred to PHCs 
failed to link to care and another 15% linked only after their supply 
of medication had run out, suggesting a gap in treatment.[5] Other 
evidence from a large inner city hospital in Johannesburg shows that 
nearly a quarter (23%) of TB patients failed to link to PHCs. Among 
the successful referrals, close to a third (30%) took place after the 
patient’s TB treatment supply expired,[7] suggesting that there remains 
considerable room for strengthening linkage to TB care.
The study clinics had the same male/female ratio (1.3) seen in 
nationally reported data,[1] although we did not observe gender 
differences across treatment outcomes, as has been documented in 
SA.[9] We also found that 71% of patients were HIV co-infected, which 
is slightly higher than the national average of 61%.[1] While this rate 
is very high, the proportion of TB patients starting treatment with 
an unknown HIV status has dropped considerably in recent years 
(from 41% in 2009 to just 7% in 2014) and the proportion of HIV-
positive TB patients on ART has increased dramatically (from 16% 
in 2009 to 79% in 2014).[4] Increasing CD4 counts[8] and timely ART 
initiation are known to reduce mortality during TB therapy. [9] With 
SA guidelines prioritising the initiation of all HIV/TB co-infected 
patients (regardless of CD4 count or clinical staging),[3] increases in 
ART coverage among TB patients are likely to continue, helping drive 
reductions in TB mortality.
Results from a systematic review have shown that in settings with 
high HIV prevalence and TB incidence, HIV infection, advancing 
immunosuppression, smear-negative disease and malnutrition are 
risk factors for TB mortality.[11] Although we did not observe poorer 
treatment outcomes in HIV-positive patients, we did find that older 
age was associated with poor treatment outcomes, as documented 
elsewhere in SA.[8] Older adults are more likely to experience 
comorbidities, drug-related adverse events, atypical forms of disease 
and extrapulmonary tuberculosis, which complicate diagnosis and 
treatment.[10] Although studies of TB among the elderly are limited in 
SA, data from Soweto confirm the very high rates of extrapulmonary 
TB (50%) and predisposing diseases (46%) in TB patients aged ≥65 
years,[12] suggesting that older adults may pose a growing challenge to 
TB control in the future. SA’s HIV epidemic is also ageing, with the 
prevalence of HIV in people aged ≥50 years expected to double in the 
next 30 years.[13] With HIV co-infection being the greatest risk factor 
for developing active TB and TB-related deaths,[1] the contribution 
of older HIV-positive patients to SA’s TB burden is likely to increase.
Although it is not clear how effectively DOT was implemented 
in this study, the relatively high rate of treatment success among all 
study participants (with or without trained supervisors) suggests that 
trained supervision had little impact on this outcome compared with 
self-administered or family-supervised treatment. This interpretation 
is in line with a recent Cochrane review,[14] which evaluated the results 
of 11 randomised controlled trials (5 662 participants) and concluded 
that there was little evidence that DOT has an impact on adherence 
during TB treatment. These findings suggest that self-administered 
TB treatment could potentially free up caregiver or healthcare worker 
time and clinic space for other health interventions.
Study limitations
This study has several limitations. Data were collected from TB 
registers and patient records available at the study sites, which varied 
in their completeness. Although we attempted to locate missing 
information, data could not always be found or verified, as was often 
true of laboratory results and the timing of HIV diagnosis. Clinic staff 
may have made errors in the transcription of treatment supervision 
type, or had different understandings of how supervision was defined. 
Since treatment supervision is captured at the start of each phase of 
TB treatment, any subsequent changes to supervision will have gone 
undocumented.
Conclusions
Based on the information recorded on the NTP clinic cards, the 
results of this analysis suggest that there is scope for substantial 
improvements in record keeping at these study sites, particularly for 
follow-up smears, cultures and DST results. Records of study visits, 
including the timing of scheduled visits v. actual visits and drug 
dispensing, are often confined to study notes or recorded haphazardly 
elsewhere on the clinic cards, despite TB cards containing a dedicated 
space to record this information. These problems may be resolved 
through careful staff training and performance monitoring, but 
other issues stem from the design of TB clinic cards themselves. 
For example, NTP clinic cards do not provide dedicated space to 
record whether laboratory tests were ordered in the first place, 
and cards printed since 2011 do not record type of DOT treatment 
supervisor. Despite these limitations, the patient outcomes reported 
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here compare well with national level data, while also highlighting 
ongoing challenges in meeting national targets for confirmed cure 
rates.
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